Studies on Pyrrolopyrimidines as Selective Inhibitors of Multidrug-Resistance-Associated Protein in Multidrug Resistance

Journal of Medicinal Chemistry

Volumn 47, Issue 6, 2004, Pages 1329-1338

  Wang, Shouming ^a,b   Folkes, Adrian ^a   Chuckowree, Irina ^a   Cockcroft, Xiaoling ^a   Sohal, Sukhjit ^a   Miller, Warren ^a   Milton, John ^a   Wren, Stephen P ^a   Vicker, Nigel ^a   Depledge, Paul ^a   Scott, John ^a   Smith, Lyndsay ^a   Jones, Hazel ^a   Mistry, Prakash ^a   Faint, Richard ^a   Thompson, Deanne ^a   Cocks, Simon ^a  

^a Cantab Pharmaceuticals Ltd   (United Kingdom)

^b Trigen Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; ANTINEOPLASTIC AGENT; DAUNORUBICIN; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN INHIBITOR; PHENETHYLPIPERAZINE; PIPERAZINE DERIVATIVE; PROTEIN INHIBITOR; PYRROLOPYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHEMICAL MODIFICATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; COMBINATORIAL CHEMISTRY TECHNIQUES; DAUNORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG SYNERGISM; FEMALE; HALF-LIFE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; PYRIMIDINES; PYRROLES; STRUCTURE-ACTIVITY RELATIONSHIP; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 12144287074     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm031011g     Document Type: Article

References (39)

1. (a) Gottesmann, M. M.; Hrycyna, C. A.; Schoenlein, P. V.; Germann, U. A. ; Pastan, I. Genetic analysis of the multidrug transporter. Annu. Rev. Genet. 1995, 29, 607-649.
2. (b) Cole, S. P. C.; Deeley, R. G. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioassays 1998, 20, 931-940.
3. Juliano, R. L.; Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 1976, 455, 152-162.
4. Cole, S. P. C.; Bhardwaj, G.; Gerlach, J. H.; Mackie, J. E.; Grant, C. E.; Almquist, K. C.; Stewart, A. J.; Kurz, E. U.; Duncan, A. M. V.; Deeley, R. G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992, 258, 1650-1654.
5. Leier, I.; Jedlitschky, G.; Buchholz, U.; Cole, S. P. C.; Deeley, R. G.; Keepler, D. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J. Biol. Chem. 1994, 269, 27807-27810.
6. Rappa, J.; Lorico, A.; Flavell, R. A.; Sartorelli, A. C. Evidence that the multidrug resistance protein (MRP) functions as a cotransporter of glutathione and natural product toxins. Cancer Res. 1997, 57, 5232-5237.
7. Cole, S. P. C.; Sparks, K. E.; Fraser, K. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 1994, 54, 5902-5910.
8. Fardel, O.; Lecureur, V.; Guillouzo, A. The P-glycoprotein multidrug transporter. Gen. Pharmacol. 1996, 27, 1283-1291.
9. Zaman, G. J. R.; Lankelma, J.; van Tellingen, O. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 7690-7694.
10. (a) Jedlitschky, G.; Leier, I.; Buchholz, U.; Barnouin, K.; Kurz, G.; Keppler, D. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res. 1996, 56, 988.
11. (b) Loe, D. W.; Almquist, K. C.; Deeley, R. G.; Cole, S. P. C. Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J. Biol. Chem. 1996, 271, 9675.
12. Kuwano, M.; Toh, S.; Uchiumi, T. Takano, H.; Kohno, K.; Wada, M. Multidrug resistance-associated protein subfamily transporters and drug resistance. Anti-Cancer Drug Des. 1999, 14, 123-131.
13. Reddy, D. S. Development of Multidrug Resistance Protein Inhibitors. Drugs Future 1997, 22 (6), 653-660.
14. Brock, I.; Hipfner, D. R.; Nielsen, B. S.; Jensen, P. B.; Deeley, R. G.; Cole, S. P. C.; Sehested, M. Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells. Cancer Res. 1995, 55, 459-462.
15. (a) Persidis, A. Cancer multidrug resistance. Nat. Biotechnol. 1999, 17, 94-95.
16. (b) Norman, B. H. Inhibitors of MRP1-mediated multidrug resistance. Drugs Future 1998, 23 (9), 1001-1013.
17. Robert, J.; Jarry, C. Multidrug Resistance Reversal Agents. J. Med. Chem. 2003, 46 (23), 4805-4817.
18. Narasaki, F.; Oka, M.; Fukuda, M.; Nakano, R.; Ikeda, K.; Takatani, H.; Terashi, K.; Soda, H.; Yano, O.; Nakamura, T.; Doyle, L. A.; Tsuruo, T.; Kohno, S. A novel quinoline derivative, MS-209, overcomes drug resistance of human lung cancer cells expressing the multidrug resistance-associated protein (MRP) gene. Cancer Chemother. Pharmacol. 1997, 40, 425-432.
19. Hyafil, F.; Vergely, C.; Duvignaud, P.; Grand-Perret, T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 1993, 53, 4595-4602.
20. Dantzig, A. H.; Shepard, R. L.; Cao, J.; Law, K. L.; Ehlhardt, W. J.; Baughman, T. M.; Bumol, T. F.; Starling, J. J. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 1996,56, 4171-4179.
21. Newman, M. J.; Rodarte, J. C.; Benbatoul K. D.; Romano S. J.; Zhang, C.; Krane, S.; Moran, E. J.; Uyeda, R. T.; Dixon, R.; Guns, E. S.; Mayer, L. D. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res. 2000, 60, 2964-2972.
22. Roe, M.; Folkes, A.; Ashworth, P.; Brumwell, J.; Chima, L.; Hunjan, S.; Prestwell, I.; Dangerfield, W.; Ryder, H.; Charlton, P. Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. Bioorg. Med. Chem. Lett. 1999, 9, 595-600.
23. Dantig, A. H.; Grese, T. A.; Norman, B. H.; Palkowitz, A. D.; Sluka, J. P.; Starling, J. J.; Winter, M. A. Benzothiphene derivatives for treating resistant tumors. Patent EP 0 773 217 Al, 1997.
24. (a) Gruber, J. M.; Norman, B. H. Methods for Inhibiting MRP1. Patent WO 9951227 A1, 1999.
25. (b) Gruber, J. M.; Hollinshead, S. P.; Norman, B. H.; Wilson, J. W. Methods for Inhibiting MRP1. Patent WO 9951236 A1, 1999.
26. (c) Gruber, J. M.; Kroin, J. S.; Norman, B. H. Methods for Inhibiting MRP1. Patent WO 9951228 A1, 1999.
27. Wang, S.; Ryder, H.; Pretswell, I.; Depledge, P.; Milton, J.; Hancox, T. C.; Dale, I.; Dangerfield, W.; Charlton, P.; Faint, R.; Dodd, R.; Hassan, S. Studies on Quinazolinones as Dual Inhibitors of Pgp and MRP1 in Multidrug Resistance. Bioorg. Med. Chem. Lett. 2002, 12, 571-574.
28. (a) Kadushkin, A. V.; Nesterova, I. N.; Golovko, T. V.; Nikolaeva, I. S. ; Pushkina, T. V.; Fomina, A. N.; Sokolova, A. S.; Chernov, V. A.; Granik, V. G. Synthesis and Biological Activity of Condensed Pyrrolo[3,2-d]pyrimidines. Pharm. Chem. J. 1990, 875-881.
29. (b) Kadushkin, A. V.; Sokolova, A. S.; Solov'eva, N. P.; Granik, V. G. Lactam Acetals and Acid Amides. 74. Studies of the Synthesis and Antitumor Activity of 5,6-Polymethylenepyrrolo[3,2-d]pyrimidines. Pharm. Chem. J. 1994, 28 (11), 792-798.
30. Echavarren, A. M.; Stille, J. K. Palladium-catalyzed coupling of aryl triflates with organostannanes. J. Am. Chem. Soc. 1987, 109, 5478-5486.
31. (a) Dube, D.; Scholte, A. A. Reductive N-Alkylation of Amides, Carbamates and Ureas. Tetrahedron Lett. 1999, 40, 2295-2298.
32. (b)Yin, J.; Buchwald, S. L. Palladium-Catalyzed Intermolecular Coupling of Aryl Halides and Amides. Org. Lett. 2000, 1101-1104
33. Dale, I. L.; Tuffley, W.; Callaghan, R.; Holmes, J. A.; Martin, K.; Luscombe, M.; Mistry, P.; Ryder, H.; Stewart, A. J.; Charlton, P.; Twentyman, P. R.; Bevan, P. Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative. Br. J. Cancer 1998, 78, 885-892.
34. Wrighton, S. A.; Stevens, J. C. The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol. 1992, 22, 1-21.
35. Shimada, T.; Yamazaki, H.; Mimura, M.; Inui, Y.; Guengerich, F. P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 1994, 270, 414-423.
36. Systematic SAR on CYP 3A4 activity in this series was not conducted. However, 3-pyridyl compounds were reported to show more potent activity against CYP 3A4 than 2-pyridyl compounds. Riley, R. J.; Parker, A. J.; Trigg, S.; Manners, C. N. Development of a Generalized, Quantitative Physicochemical Model of CYP 3A4 Inhibition for Use in Early Drug Discovery. Pharm. Res. 2001, 18 (5), 652-655.
37. Mao, Q.; Deeley, R. G.; Cole, S. P. Functional reconstitution of substrate transport by purified multidrug resistance protein MRP1 (ABCC1) in phospholipid vesicles. J. Biol. Chem. 2000, 275, 34166-34172.
38. Barecki, M. E.; Casciano, C. N.; Johnson, W. W.; Clement, R. P. In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. Drug Metab. Dispos. 2001, 29 (9), 1173-1175.
39. Mistry, P.; Stewart, A. J.; Dangerfield, W.; Okiji, S.; Liddle, C.; Bootle, D.; Plumb, J. A.; Templeton, D.; Charlton, P. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res. 2001, 61, 749-758.